Category Archives: Global News Feed


Stem Cell Clinic > Global News Feed

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

By Global News Feed

Boca Raton, Florida, Oct. 11, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s Disease (AD), today announced that management will participate in the upcoming Maxim Healthcare Virtual Summit, to be held October 15-17, 2024.

Here is the original post:
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

Firefly Neuroscience to Participate in Upcoming October Investor Conferences

By Global News Feed

TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that management will participate in the following October 2024 investor conferences:

See the article here:
Firefly Neuroscience to Participate in Upcoming October Investor Conferences

PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing

By Global News Feed

Groundbreaking collaboration to unlock the full potential of PacBio’s Onso technology, accelerating breakthroughs in cancer genomics across Asia Groundbreaking collaboration to unlock the full potential of PacBio’s Onso technology, accelerating breakthroughs in cancer genomics across Asia

Continue reading here:
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

By Global News Feed

Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the Company’s abstract “Varoglutamstat Increases Glomerular Filtration in Elderly Patients without Signs of Proteinuria and Potentially Offers a New Approach to Treat Diabetic Kidney Disease (DKD)” has been selected for a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, California, held October 23 to 27.

The rest is here:
Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

By Global News Feed

WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announces updates on its growing therapeutic pipeline, designed to meet the high unmet needs of cancer patients. The company is pursuing a prudent commercialization strategy with a focus on its ExacTcell™ technology platform, which leverages precision T cell therapies to address supportive care for cancer patients.

View post:
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

By Global News Feed

WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from October 23-27, 2024.

Originally posted here:
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024

By Global News Feed

WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to share its $1B+ revenue potential, a reflection of the company’s novel business approach.

See original here:
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024

→←